Pharma channel feed

Take­da takes $770M write­down on failed stem cell ther­a­py and with­drawn can­cer drug

Last year

Like Mod­er­na, pan­dem­ic peers Pfiz­er and BioN­Tech head to PhI­II with Covid/flu com­bo jab

Last year
R&D
Coronavirus

In­ject­ed form of Leqem­bi ap­pears ef­fec­tive at clear­ing amy­loid, but with no­table risks

Last year
R&D

ACIP rec­om­mends rou­tine use of mpox vac­cine for at-risk adults, open­ing the door to po­ten­tial 2024 launch

Last year
FDA+

No­var­tis re­fresh­es Kisqali metasta­t­ic breast can­cer cam­paign with mes­sage to both ‘live longer and live well’

Last year
Marketing

GSK says RSV vac­cine trig­gered im­mune re­sponse in adults as young as 50 years old

Last year

GHMC health­care net­work ex­pands south, part­ners with Mex­i­co-based agency

Last year
Marketing

NIH nom­i­nee Mon­i­ca Bertag­nol­li clears Sen­ate pan­el with bi­par­ti­san sup­port de­spite Sanders’ drug pric­ing qualms

Last year
People
FDA+

Scoop: Mer­ck scraps PhII tri­als of Alzheimer’s and de­pres­sion small mol­e­cule af­ter liv­er tox­i­c­i­ty ob­ser­va­tions

Last year
R&D

Dana­her’s third-quar­ter rev­enue from biotech ser­vices down 19% amid slow­down in Chi­na, US

Last year
China
Outsourcing

FDA ex­pect­ed to de­cide on As­traZeneca's self-ad­min­is­tered flu vac­cine next quar­ter

Last year
FDA+

Sam­sung adds an­oth­er Lu­cen­tis in­ter­change­able biosim­i­lar to the mix

Last year
FDA+

Bio­gen, GSK, No­vo Nordisk and five oth­er bio­phar­mas land on an­nu­al list of best in­ven­tions for 2023

Last year
Marketing

Am­gen to cut 350 staffers fol­low­ing $28B Hori­zon takeover

Last year
People

Sanders goes af­ter NIH for grant­i­ng ex­clu­sive patent for po­ten­tial can­cer ther­a­py

Last year
FDA+

Mer­ck KGaA rais­es aware­ness for smol­der­ing MS symp­toms that cause pa­tients to 'un­rav­el'

Last year
Marketing

How No­vo Nordisk’s Ry­bel­sus went from pan­dem­ic washout to block­buster, and what’s next for oral weight loss

Last year
Marketing

Mar­ket­ingRx roundup: Fishawack re­brands as Avalere Health; BMS, Gilead, Am­gen re­up clin­i­cal di­ver­si­ty pro­gram

Last year
Marketing

Up­dat­ed: No­var­tis 'on track' to com­plete re­struc­tur­ing post San­doz spin, push­es back Plu­vic­to fil­ing

Last year
R&D

Idor­sia lays off up to 300 peo­ple, plans for pipeline pri­or­i­ti­za­tion in ef­fort to ex­tend cash run­way

Last year
People

Sanofi and Re­gen­eron's block­buster Dupix­ent re­ject­ed by FDA for chron­ic hives con­di­tion

Last year
FDA+

FDA ap­proves first sub­cu­ta­neous ver­sion of block­buster IBD drug in­flix­imab

Last year
FDA+

Why is­n't Ver­tex de­clar­ing suc­cess for its non-opi­oid pain drug in a late-stage tri­al?

Last year

Pe­di­atric la­bels: FDA ex­pands can­cer and dwarfism drugs from Genen­tech and Bio­Marin

Last year
FDA+
First page Previous page 949596979899100 Next page Last page
A service from the Financial Times